Tamoxifen was licensed for use in the US for advanced breast cancer patients in 1972, and its current success in treating patients with ER positive breast cancers has been called a catalyst for the precision medicine approach to cancer therapy [16]. Here, ESR1 is linked to breast carcinoma.